Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEmmerson Plc Regulatory News (EML)

Share Price Information for Emmerson Plc (EML)

Share Price is delayed by 15 minutes
Get Live Data
2.10    0.00 (0.00%)
Bid:
2.00
Ask:
2.20
Spread: 0.20 (10.00%)
Market Cap: £28.06m
EML Live PriceLast checked at - London Stock Exchange

Intraday Emmerson Plc Share Chart

Q2 Update

5 Jul 2024 07:00

RNS Number : 2470V
Emmerson PLC
05 July 2024
Β 

Β 

5 July 2024

Β 

Emmerson PLC ("Emmerson" or the "Company")

Q2 2024 Update

Β 

Emmerson, the Moroccan-focused potash development company, is pleased to provide an update on activities during Q2 2024 from itsΒ 100% owned Khemisset Potash ProjectΒ ("Khemisset" or the "Project").

Β 

Highlights

Β· Updated Environmental & Social Impact Assessment (''ESIA'') submitted, incorporating the optimisations from the Khemisset Multi-mineral Process ("KMP"). ESIA currently under review by the Commission RΓ©gionale UnifiΓ©e de l'Investissement ("CRUI")

Β· Initial crop trials completed, successfully demonstrating the effectiveness of KMP products as sources of phosphate. Further trials are planned to confirm the benefits of the additional contained micro-nutrients magnesium and iron

Β· Offtake Memorandum of Understanding ("MOU") signed for KMP products, in addition to existing MOUs for potash and salt

Β· Patent application for KMP now submitted in Morocco as well as the UK

Β· US$2.5 million raised from a placing at 1.75 pence in April 2024, including US$2.2 million from the Company's largest shareholders, and US$0.3 million from an oversubscribed retail offer

Β 

Chief Executive Graham Clarke said: "Following the positive news at the end of Q1 that our recourse application for the environmental approval had been upheld and would be referred back to the CRUI for reconsideration, we were delighted to update our ESIA to show the significant improvements brought about by the KMP optimisations in addition to the previous design optimisations. The overall environmental credentials of the Project are now even more robust, and, together with the compelling economics of the KMP update, should mean that we can obtain the necessary approvals and move forward with the Project swiftly.

Β 

"While we have been holding back from any major workstreams pending timing clarification of the ESIA approval process, we have nevertheless made some important steps forward on the new KMP products to be marketed.

Β 

"The crop trials, which were completed in June, confirmed the effectiveness of the new KMP fertiliser products as sources of phosphate and will be followed up with further trials looking at the benefits of the other micronutrients (magnesium and iron) they contain, as well as their slow-release properties. We have also signed MOUs for the offtake of a significant quantity of the new KMP products, confirming the marketability of these multi-nutrient fertilisers."

Β 

Environmental Approval

In March 2024, the Commission MinistΓ©rielle de PilotageΒ (The "Ministerial Committee") invited the Company to update its ESIA to incorporate the optimisations arising from the KMP process changes, which include a significant reduction in water consumption and the elimination of the need to dispose of waste brines, and to resubmit this for review by the CRUI.

Β 

In April 2024, the Company completed these updates and resubmitted what it hopes to be the last version of the ESIA.

Β 

The Company continues to pursue its engagement with the relevant authorities, and in view of the considerable improvements to the environmental footprint of the Project made not only through the KMP enhancements, but also other enhancements over the previous three years, the Company remains confident that the approval will be forthcoming.

Β 

Crop trials

In June 2024, the Company completed the first set of crop trials using two multi-nutrient fertilisers produced from the new KMP optimisations. The trials, which took place over a 10-week period with little gem lettuces in a glass-house test environment, assessed the suitability of struvite and vivianite products as sources of phosphate.

Β 

The results were positive as had been expected, as plants fed with both products performed in line with those given traditional phosphate sources, and considerably better than controls given no phosphate.

Β 

Further trials are planned to assess the additional benefits from the other nutrients contained by the KMP products (magnesium, iron and nitrogen), as well as the benefit of being slow-release, on various crops and for different soil types, with a view to increasing their market value.

Β 

Offtake for KMP products

In June 2024, the Company entered into a non-binding MOU with Hexagon Group AG ("Hexagon") for offtake of some of the new fertiliser products resulting from KMP.

Β 

Under the terms of the MOU, Hexagon would take up to 300,000 metric tonnes of struvite-based products and 50,000 tonnes per annum of vivianite-based products

Β 

All other terms of the MOU are in line with the MOUs for potash and salt announced in November 2022, including "take or pay" provisions, and will be delivered Free On Board ("FOB") at Casablanca, Jorf Lasfar, or Safi (unless otherwise mutually agreed).

Β 

This MOU is also non-exclusive, meaning the Company can continue to engage in ongoing offtake discussions with other wholesale customers, distributors, and global traders for production from Khemisset for all of its products.

Β 

Other

Following the submission of a patent application for the new KMP processes in the UK in September 2023, the Company also submitted an application in Morocco during Q2 2024. These patent applications, which will be extended more widely once approved, give important commercial protections over the intellectual property relating to this valuable innovation.

Β 

Equity placing

In April, the Company announced the completion of an equity placing which raised US$2.5 million in gross proceeds at a price of 1.75 pence per share (the "Placing Price").

Β 

The bulk of this placing was with Global Sustainable Minerals Pte Ltd ("GSM") and Gold Quay Capital Pte Ltd ("GQC") (together the "Strategic Investors"), whereby GSM subscribed for US$2.0 million and GQC for US$175k of new shares, at the Placing Price. As a result of this placing, GSM received 90,702,948 shares and GQC received 7,936,508, taking their holdings to 20.30% and 2.64% respectively.

Β 

The Strategic Investors also received a warrant to subscribe for new Shares ("Warrants") for each new share received in this placing, at an exercise price of 3 pence and an expiry date of 31 December 2024.

Β 

In addition, the Company completed an oversubscribed retail offering on the REX platform, raising a further US$0.3 million (Β£240k) at the Placing Price.

Β 

The funds are to be used by the Company to advance its studies in respect of KMP towards feasibility level alongside the progression of the EIA process in Morocco, as well as for general working capital requirements.

Β 

Outlook

The key priority over Q3 remains obtaining environmental approval for the Project. At the same time, the Company is continuing with low cost/high value testwork related to KMP including crop trials, technical workshops, and production optimisations both in Morocco and the UK.

Β 

**ENDS**

Β 

For further information, please visitΒ www.emmersonplc.com, follow us on Twitter (@emmerson_plc), or contact:

Β 

Emmerson PLC

Graham Clarke / Jim Wynn / Charles Vaughan

Β 

Β 

+44 (0) 207 138 3204

Panmure Liberum Limited (Nominated Advisor and Joint Broker)

Scott Mathieson / Matthew Hogg

Β 

Β 

+44 (0)20 3100 2000

Shard Capital (Joint Broker)

Damon Heath / Isabella Pierre

Β 

+44 (0)20 7186 9927

Β 

BlytheRay (Financial PR and IR)

Tim Blythe / Megan Ray / Said Izagaren

Β 

+44 (0) 207 138 3204

Β 

Notes to Editors

Emmerson is focused on advancing the Khemisset project ("Khemisset" or the "Project") in Morocco into a low cost, high margin supplier of potash, and the first primary producer on the African continent. With an initial 19-year life of mine, the development of Khemisset is expected to deliver long-term investment and financial contributions to Morocco including the creation of permanent employment, taxation, and a plethora of ancillary benefits. As a UK-Moroccan partnership, the Company is committed to bringing in significant international investment over the life of the mine.

Β 

Morocco is widely recognised as one of the leading phosphate producers globally, ranking third in the world in terms of tonnes produced annually, and the development of this mine is set to consolidate its position as the most important fertiliser producer in Africa. The Project has a large JORC Resource Estimate (2012) of 537Mt @ 9.24% K2O, with significant exploration potential, and is perfectly located to support the expected growth of African fertiliser consumption whilst also being located on the doorstep of European markets. The need to feed the world's rapidly increasing population is driving demand for potash and Khemisset is well placed to benefit from the opportunities this presents. The Feasibility Study released in June 2020 indicated the Project has the potential to be among the lowest capital cost development stage potash projects in the world and also, as a result of its location, one of the highest margin projects. Updated financial estimates published in February 2024 indicated a net present value of US$2.2 billion, with an internal rate of return of approximately 40%.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
UPDQKQBDDBKBCOK
Date   Source Headline
30th Mar 20267:00 amRNSArbitration Memorial Submission
24th Mar 20267:00 amRNSResult of WRAP Retail Offer
20th Mar 20267:31 amRNSWRAP Retail Offer for up to £100,000
20th Mar 20267:30 amRNSResult of Placing and Subscription
20th Mar 20267:00 amRNSProposed Placing and Subscription
22nd Jan 20267:00 amRNSArbitration Update
26th Nov 20257:00 amRNSAppointment of Joint Broker
30th Sep 20257:00 amRNSInterim Results
24th Jul 202512:31 pmRNSResult of Annual General Meeting
1st Jul 20257:00 amRNSNotice of AGM
30th Jun 20253:36 pmRNS2024 Financial Results
1st May 20258:10 amRNSRequest for Arbitration
17th Mar 20257:00 amRNSLitigation Funding Update
13th Jan 20253:03 pmRNSAdditional Issuance of Shares and Rights
2nd Jan 20257:00 amRNSLitigation Funding Secured
12th Dec 20247:00 amRNSAdditional Issuance of Shares and Rights
6th Dec 20247:01 amRNSFundraising of £0.85 million
1st Nov 20247:00 amRNSNotice of dispute with Moroccan Government
28th Oct 20247:00 amRNSESIA Process, Board Changes, and Cash Management
14th Oct 20247:00 amRNSESIA Update
27th Sep 20247:00 amRNSInterim Results and Q3 Update
5th Jul 20247:00 amRNSQ2 Update
1st Jul 20247:00 amRNSChange of Nominated Advisor and Joint Broker
26th Jun 202411:33 amRNSResult of Annual General Meeting
31st May 202410:56 amRNSGrant of Share Options and PDMR dealing
31st May 20247:00 amRNSNotice of AGM and Posting of Annual Report
24th May 20247:00 amRNS2023 Financial Results
22nd Apr 202411:47 amRNSTR-1: Notification of major holdings
8th Apr 20244:45 pmRNSResults of Oversubscribed REX Retail Offer
8th Apr 20247:01 amRNSREX Retail Offer
8th Apr 20247:00 amRNSQ1 Update, Equity Placing and Retail Offer
11th Mar 20247:00 amRNSCommittee Upholds Environmental Approval Referral
1st Feb 20247:00 amRNSScoping Study on Breakthrough New Processing Route
8th Jan 20247:00 amRNSQ4 Update
21st Dec 20237:00 amRNSExtension of Mandated Lead Arrangers
26th Sep 20237:00 amRNSInterim Results for the six months to 30 June 2023
21st Sep 20237:00 amRNSQ3 2023 and Financing update
11th Sep 202311:38 amRNSMorocco Statement
11th Jul 202311:57 amRNSDirector/PDMR Shareholding
10th Jul 20234:30 pmRNSDirector/PDMR Shareholding
6th Jul 20232:49 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSQ2 Update
6th Jun 20237:00 amRNSExercise & Allotment of Shares
31st May 202312:01 pmRNSResult of AGM
5th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
13th Apr 20237:00 amRNS2022 Financial Results and Q1 Update
14th Feb 20237:00 amRNSMandated Lead Arrangers Appointed for Financing
9th Jan 20237:00 amRNSQ4 Update
3rd Jan 20237:00 amRNSAppointment of Liberum as Nominated Advisor
21st Nov 20227:00 amRNSPotash and Salt Offtake MOUs

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.